Advertisement
Rapid CommunicationMinireview—A Latin American Perspective on Ion Channels

Understanding the Bases of Function and Modulation of α7 Nicotinic Receptors: Implications for Drug Discovery

Jeremías Corradi and Cecilia Bouzat
Molecular Pharmacology September 2016, 90 (3) 288-299; DOI: https://doi.org/10.1124/mol.116.104240

Abstract

The nicotinic acetylcholine receptor (nAChR) belongs to a superfamily of pentameric ligand-gated ion channels involved in many physiologic and pathologic processes. Among nAChRs, receptors comprising the α7 subunit are unique because of their high Ca2+ permeability and fast desensitization. nAChR agonists elicit a transient ion flux response that is further sustained by the release of calcium from intracellular sources. Owing to the dual ionotropic/metabotropic nature of α7 receptors, signaling pathways are activated. The α7 subunit is highly expressed in the nervous system, mostly in regions implicated in cognition and memory and has therefore attracted attention as a novel drug target. Additionally, its dysfunction is associated with several neuropsychiatric and neurologic disorders, such as schizophrenia and Alzheimer’s disease. α7 is also expressed in non-neuronal cells, particularly immune cells, where it plays a role in immunity, inflammation, and neuroprotection. Thus, α7 potentiation has emerged as a therapeutic strategy for several neurologic and inflammatory disorders. With unique activation properties, the receptor is a sensitive drug target carrying different potential binding sites for chemical modulators, particularly agonists and positive allosteric modulators. Although macroscopic and single-channel recordings have provided significant information about the underlying molecular mechanisms and binding sites of modulatory compounds, we know just the tip of the iceberg. Further concerted efforts are necessary to effectively exploit α7 as a drug target for each pathologic situation. In this article, we focus mainly on the molecular basis of activation and drug modulation of α7, key pillars for rational drug design.

Introduction

Nicotine has been a key molecule for the advancement of pharmacology since the beginning of the 20th century, when Langley (1905), through fundamental experiments, concluded that muscle contraction was mediated by a “receptive substance” present on the muscle. The muscle nicotinic acetylcholine receptor (nAChR) was thus a pillar in the discovery of neurotransmitter receptors (Langley, 1905). Still, it was not until 1970 that the first neurotransmitter receptor, nAChR, was identified (Changeux et al., 1970; Miledi and Potter, 1971). With the later advent of the molecular biology revolution in the 1980s, the nAChR family was first identified and an extended family of homologous pentameric receptors was revealed (Patrick et al., 1983; Le Novère and Changeux, 1995). This class of receptors was first known as Cys-loop receptors because all family subunits contain a conserved pair of disulfide-bonded cysteines separated by 13 residues. The discovery of orthologs in prokaryotes (Tasneem et al., 2005), which lack the double cysteines, has extended the Cys-loop family to the superfamily of pentameric ligand-gated ion channels (pLGIC).

In vertebrates, the pLGIC superfamily includes cationic channels, nAChRs and serotonin 5-HT3 receptors, and anionic channels activated by GABA or glycine (Le Novère and Changeux, 2001; Lester et al., 2004; Sine and Engel, 2006; Bartos et al., 2009). Their vital role in converting chemical recognition into an electrical impulse makes these receptors prime loci for learning, memory, and disease processes, as well as targets for clinically relevant drugs.

The nAChR is widely distributed throughout the animal kingdom, from nematodes to humans (Le Novère and Changeux, 1995). nAChRs are expressed in many regions of the central and peripheral nervous system, in addition to non-neuronal tissues. The muscle nAChR plays a major role in neuromuscular transmission and is the target of muscle relaxants (Sine, 2012), whereas nAChRs in the brain represent a broad heterogeneous family of ubiquitously expressed receptors. nAChR responses to endogenous acetylcholine (Ach) and choline and exogenous nicotine are involved in a number of physiologic processes and pharmacological effects (Dani and Bertrand, 2007; Albuquerque et al., 2009; Hurst et al., 2013).

The homopentameric α7, one of the most abundant nAChRs in the nervous system, is also expressed in many non-neuronal cells. Its unique activation properties, high calcium permeability, ionotropic/metabotropic dual action, ubiquitous distribution, and involvement in a range of neurologic, psychiatric, and inflammatory disorders have made α7 an important emerging drug target; the participation of α7 in pathologic conditions and the therapeutic potential of α7 ligands has been well documented (see for example Taly and Changeux, 2008; Wallace and Porter, 2011; Lendvai et al., 2013; Wallace and Bertrand, 2013; Uteshev, 2014; Dineley et al., 2015). In this article, we focus on the unique properties of activation and drug modulation of α7 and its relationship with disease and therapy.

nAChR Structure and Function

nAChR subunits are classified as two types, α and non-α, with the α-type containing a disulfide bridge in the agonist binding site. Five muscular (α1, β, γ, ε, and δ) and eleven neuronal (α2–α7, α9, α10, and β2–β4) nAChR subunits have been identified in the mammalian genome (ligand-gated ion channel database, http://www.ebi.ac.uk/compneur-srv/LGICdb/cys-loop.php).

nAChRs are assembled from five identical (α7 or α9) or different subunits (at least two α-type subunits), and can form a variety of different heteromeric receptors with a broad spectrum of pharmacological and kinetic properties (Fig. 1). The resolution of the three-dimensional structures of pLGICs has been the subject of intense efforts over the last decade (Brejc et al., 2001; Dellisanti et al., 2007; Hilf and Dutzler, 2008, 2009; Bocquet et al., 2009; Hibbs and Gouaux, 2011; Corringer et al., 2012; Hassaine et al., 2014; Miller and Aricescu, 2014; Sauguet et al., 2014; Cecchini and Changeux, 2015). However, no high-resolution structure of the full length α7 has been reported to date; an extracellular domain of α7/AChBP chimera (Li et al., 2011; Nemecz and Taylor, 2011) and a nuclear magnetic resonance (NMR) structure of α7 transmembrane domain have been described (Bondarenko et al., 2014).

Fig. 1.
Fig. 1.

Models of pentameric arrangements of homomeric and some heteromeric nAChRs. α7 and α9 are the only α-type subunits capable of forming functional homomeric receptors, which contain five identical binding sites. In α7, occupancy of only one site is required for activation. Examples of possible combinations of α and non-α subunits in heteromeric arrangements are shown. An α-type subunit is required for the principal face of the binding site. The muscle nAChR contains two functional binding sites at α/δ and α/ε(γ) interfaces. Some subunits can assemble with different stoichiometries, such as α4 and β2. In addition to the arrangement shown, (α4)3(β2)2 receptors are also functional.

All pLGICs share a conserved organization with five subunits symmetrically arranged around a central ion pore (Fig. 2). Functional domains include the extracellular domain (ECD), which carries the agonist binding sites at subunit interfaces; the transmembrane domain (TMD), which contains the ion pore and the gate; and the intracellular domain (ICD), which contains determinants of channel conductance and sites for regulation and intracellular signaling (Paulo et al., 2009; Jones et al., 2010; King et al., 2015) (Fig. 2). The interface between the ECD and TMD, also referred to as the coupling region, is important for coupling agonist binding to channel opening (Bouzat et al., 2004; Lee and Sine, 2005; Castillo et al., 2006; Bartos et al., 2009), as well as for determining open channel lifetime and rate of desensitization (Bouzat et al., 2008; Yan et al., 2015) (Fig. 2).

Fig. 2.
Fig. 2.

Structural model of pLGICs. The ECD is folded into a highly conserved immunoglobulin-like β-sandwich. The agonist binding site is found in a cavity at an interface between two adjacent subunits (Sine, 2012). The principal or positive face is provided by an α-type subunit and includes three loops that span β strands (named as Loops A–C) that harbor predominantly aromatic residues essential for binding and gating. The adjacent subunit, which forms the complementary or minus face, contributes with residues clustered in segments called Loops D–F (Brejc et al., 2001; Sine, 2012). ACh docked into the binding site is shown (α7/AChBP chimera, pdb code 3SQ6). Key aromatic residues from the principal face are Tyr188, Trp149, and Tyr93, and from the minus face, Trp55. The transmembrane domain (TMD) is composed of four transmembrane-spanning helices (TM1–TM4). The TM2 forms the walls of the ion pore, which contains the gate (ring of leucines at 9′ position) and determinants for selectivity. The outer ring of fifteen α-helices (TM1, TM3, and TM4) shields the inner TM2 ring from the lipids (reviewed in Althoff et al., 2014). The interface between the ECD and TMD, also named as coupling region, includes the conserved Cys-loop (β6β7 loop), β1β2 and β8β9 loops from the ECD, and the M2–M3 linker from the TMD. The long intracellular region (ICD) between TM3 and TM4 is highly variable and particularly short in prokaryotic pLGICs. It is thought to be associated with cytoskeletal proteins and involved in channel modulation in all pLGICs (Kabbani et al., 2013). As shown in the figure, in α7, this region contains determinants of channel conductance (Andersen et al., 2011, 2013) and mediates several intracellular signals (Paulo et al., 2009; Jones et al., 2010).

The possible structural events that translate neurotransmitter binding at the ECD into opening of the transmembrane ion channel 60 Å away is an issue of intense research that has been discussed in recent reviews (Corringer et al., 2012; Althoff et al., 2014; Sauguet et al., 2014; Cecchini and Changeux, 2015). On the basis of the Monod-Wyman-Changeux model (Monod et al., 1965), the functional response of a pLGIC can be interpreted as a selection from a few global and discrete conformations elicited by the binding of agonist: closed, open, and desensitized, the latter showing high agonist affinity at the same time being impermeable to ions (Zhang et al., 2013) (Fig. 3). Intermediate states between closed and open or open and desensitized states have been proposed for nAChRs and several pLGICs (Lape et al., 2008; Corradi et al., 2009; Mukhtasimova et al., 2009; Cecchini and Changeux, 2015). Therefore, the number of states in the main conformations and the rate of transition between states determine receptor kinetics, and this tunes each receptor to its physiologic role. In turn, drugs, by binding to different states, can differently modulate receptor function.

Fig. 3.
Fig. 3.

Minimal model of nAChR activation. pLGICs have three main classes of conformational states: Closed (C), open (O), and desensitized (D). Intermediate states have also been detected.

α7 in the Nervous System in Healthy and Disease States

α7 is one of the most abundant nAChRs in the central nervous system. It is particularly expressed in regions implicated in cognitive function and memory, such as hippocampus, cortex, and several subcortical limbic regions (see Lendvai et al., 2013). It is also expressed on non-neuronal cells, including astrocytes, microglia, oligodendrocyte precursor cells, and endothelial cells, where it plays a role in immunity, inflammation, and neuroprotection (Shytle et al., 2004; Shen and Yakel, 2012; Dineley et al., 2015).

In neurons, α7 receptors localize presynaptically on GABAergic and glutamatergic terminals in the hippocampus and other regions to facilitate release of neurotransmitters. Postsynaptically, α7 receptors mediate fast synaptic transmission, and in perisynaptic locations they modulate other inputs to neurons and activate a variety of signaling pathways through volume transmission (Gotti and Clementi, 2004; Jones and Wonnacott, 2004; Dani and Bertrand, 2007; Dickinson et al., 2008; Albuquerque et al., 2009; Sinkus et al., 2015) (Fig. 4).

Fig. 4.
Fig. 4.

Neurotransmission mediated by α7 in the mammalian brain. α7 receptors can be postsynaptic, presynaptic (with a role in regulation of neurotransmitter release), or perisynaptic when they are involved in volume transmission.

α7 contributes to cognitive functioning, sensory processing information, attention, working memory, and reward pathways, and a large body of evidence shows that enhancing α7 activity improves attention, cognitive performance, and neuronal resistance to injury (reviewed in Uteshev, 2014). Significant reduction of α7 in the brain, particularly in the hippocampus, has been reported in Alzheimer disease (Guan et al., 2000; Kadir et al., 2006) and schizophrenic patients (Schaaf, 2014; Dineley et al., 2015). The α7 gene, CHRNA7 on chromosome 15, is genetically linked to multiple disorders with cognitive deficits, including schizophrenia, intellectual disability, bipolar disorder, autism spectrum disorders, attention deficit hyperactivity disorder, epilepsy, Alzheimer disease, and sensory processing deficit (Sinkus et al., 2009, 2015; Schaaf, 2014; Dineley et al., 2015; Deutsch et al., 2016). A partial duplication of CHRNA7 resulting in the chimeric gene CHRFAM7A, which is present only in humans, has been associated with schizophrenia (Sinkus et al., 2009; Neri et al., 2012). Its gene product, dupα7, lacks part of the binding site and may act as a negative modulator of α7 (Wang et al., 2014).

Despite its homomeric character, α7 can assemble with other subunits to form heteromeric receptors. In particular, α7β2 heteromeric receptors have been detected in several brain areas (Liu et al., 2009, 2012; Moretti et al., 2014; Thomsen et al., 2015; Zoli et al., 2015). Interestingly, α7β2 are highly sensitive to blockade by Aβ1–42, suggesting that they may play a unique role in the neuropathology of Alzheimer disease (Liu et al., 2009). Additionally, these heteromeric receptors exhibit high sensitivity to volatile anesthetics, and therefore could be targets for anesthetic action (Mowrey et al., 2013). Thus, α7β2 nAChR may represent a novel molecular target requiring selective α7β2 ligands.

Extraneuronal α7 and Its Pleiotropic Roles

α7 is present in various non-neuronal tissues, such as glia (Sharma and Vijayaraghavan, 2001), blood cells (Kawashima and Fujii, 2004; De Rosa et al., 2005; Báez-Pagán et al., 2015), keratinocytes (Maus et al., 1998), epithelial cells and fibroblasts (Zia et al., 1997), endothelial cells (Macklin et al., 1998), cells of the digestive system and lung cells (reviewed in Wessler and Kirkpatrick, 2008), spermatogonia, spermatocytes, and seminiferous tubular and Sertoli cells (Schirmer et al., 2011). The functional role of α7 in these cells is being intensively investigated and has been associated with differentiation, migration, adhesion, cell contact, apoptosis, and angiogenesis processes (Ni et al., 2010; Egea et al., 2015; Zdanowski et al., 2015).

In particular, α7, present in all types of immune cells, including lymphocytes (T and B cells), dendritic cells and macrophages (reviewed in Egea et al., 2015), has attracted considerable attention as an important drug target for inflammation. α7 is an important player in the “cholinergic anti-inflammatory pathway,” which is a link between vagal efferent fibers and innate immune system (Martelli et al., 2014). α7 modulates intracellular signal pathways [Janus kinase 2 (JAK2)/signal transducer and activator of transcription (STAT3) and PI3K/Akt] in immune cells, which results in potent anti-inflammatory effects through cytokine production inhibition and overexpression of heme oxygenase 1 (Báez-Pagán et al., 2015; Egea et al., 2015) (Fig. 5). A brain cholinergic pathway also exists that regulates microglial activation through α7 (Shytle et al., 2004). This pathway is crucial for neuroprotection (Park et al., 2007) and is probably important in Parkinson disease (Stuckenholz et al., 2013), oxygen and glucose deprivation (Parada et al., 2013), and global ischemia (Guan et al., 2015).

Fig. 5.
Fig. 5.

Dual ionotropic/metabotropic nature of α7: Intracellular pathway signaling mediated by α7 activation. α7 allows transient flux of Na+, K+, and Ca2+. The transient increase of calcium may also lead to a sustained calcium response by a calcium-induced calcium release (CICR) mechanism through IP3 receptors. As a metabotropic receptor, α7 mediates intracellular signals by binding to Gα and Gβγ proteins and several other partners (Kabbani et al., 2013; King et al., 2015). In immune cells, α7 has been shown to be involved in several intracellular pathways; although not yet fully deciphered mechanistically, these pathways lead to potent anti-inflammatory effects. For example, α7 has been shown to activate JAK2/STAT3 in some immune cells, which leads to blockade of nuclear factor (NF)-κB nuclear translocation and inhibition of NF-κB, resulting in inhibition of proinflammatory cytokine production. Also, α7 has been shown to activate the PI3K/Akt pathway that promotes Nrf-2 translocation to the nucleus and overexpression of heme oxygenase 1 (HO-1), resulting in potent anti-inflammatory effects (see de Jonge and Ulloa, 2007; Báez-Pagán et al., 2015; Egea et al., 2015). DAG, diacylglycerol; GPCR, G protein-coupled receptor; PKC, protein kinase C; ROS, reactive oxygen species.

Therefore, α7 nAChR is emerging as an important drug target for the modulation of inflammation in different pathologic contexts, including sepsis, ischemia/reperfusion, rheumatoid arthritis, and pancreatitis.

α7 Pharmacology and Ion Selectivity

Hallmark features of α7 receptors include high Ca2+ permeability, relatively low sensitivity to ACh, full activation by choline, high-affinity for α-bungarotoxin (α-BTX), relatively low affinity for nicotine, and fast desensitization that occurs on the submillisecond time scale.

Dose-response curves show EC50 values of ∼100–200 μM for ACh [Hill coefficient (nH) ∼1] (Andersen et al., 2013), 0.4–1.6 mM for choline, and 18–91 μM for nicotine (Wonnacott and Barik, 2007). Several α7-specific agonists have been synthetized, including PNU-282987 (EC50 128 nM), AR-R17779 (EC50 ∼10–20 μM), compound A (EC50 ∼14 nM to 0.95 μM), and partial agonists GTS-21 (EC50 ∼6–26 μM), and SSR180711 (EC50 ∼1–4 μM). Selective competitive antagonists are α-BTX (IC50 ∼1–100 nM), which has been widely used to detect α7 in tissues, and methyllycaconitine (MLA, IC50 10–200 nM) (Wonnacott and Barik, 2007).

α7 allows flux of Na+ and K+ and is highly permeable to Ca2+. The PCa2+/PNa+ ratio is ∼10–20, which is greater than that of other nAChRs and similar to N-methyl-d-aspartate receptors (Séguéla et al., 1993; Albuquerque et al., 1997). The high Ca2+ permeability underlies most of α7 functions: facilitation of neurotransmitter release, depolarization of postsynaptic cells, and initiation of many cellular processes through its action as a second messenger (Gotti and Clementi, 2004). The transient increase in intracellular Ca2+ is converted into a sustained, wide-ranging phenomenon by calcium release from intracellular stores through a calcium-induced calcium release mechanism, a process involving IP3 and ryanodine receptors (Tsuneki et al., 2000; Dajas-Bailador et al., 2002; Guerra-Álvarez et al., 2015) (Fig. 5).

The concept of α7 as a dual metabotropic/ionotropic receptor is attracting increasing attention (Kabbani et al., 2013). α7 binds both Gα and Gβγ proteins through the M3–M4 loop and enables a downstream calcium signaling response that can persist beyond the expected time course of channel activation (Fig. 5) (Kabbani et al., 2013; King et al., 2015). Moreover, in lymphocyte T cells, mobilization of Ca2+ through the α7 channel is not necessarily required for the nicotine-induced release of Ca2+ from the internal stores (Razani-Boroujerdi et al., 2007). Channel-independent signal transduction has been related to the role of α7 in inflammation (de Jonge and Ulloa, 2007; Thomsen and Mikkelsen, 2012) and in neurite growth (Nordman and Kabbani, 2012; Kabbani et al., 2013).

α7 is not only permeable to Ca2+ but is also modulated by the ion; Ca2+ has been shown to regulate agonist efficacy and cooperativity (Bonfante-Cabarcas et al., 1996; Albuquerque et al., 1997). As in other pLGICs (Zimmermann et al., 2012), the divalent modulatory sites may be located at the ECD.

α7 Channel Kinetics

Heterologous expression of α7 in oocytes and mammalian cells combined with electrophysiological experiments has provided information about the receptor’s unique activation properties. The surface expression of recombinant α7 requires coexpression of the chaperone RIC-3 (Williams et al., 2005), a transmembrane protein that is required for efficient receptor folding, assembly, and functional expression (Castillo et al., 2005; Millar, 2008). Recently, another chaperone, NACHO, has been identified. NACHO is a transmembrane protein of neuronal endoplasmic reticulum that mediates assembly of α7 by promoting protein folding, maturation through the Golgi complex, and expression at the cell surface (Gu et al., 2016).

Typical α7 receptor-mediated currents decay rapidly in the presence of agonist as a result of desensitization (Fig. 6A). Given the fast kinetics, the temporal resolution of agonist exchange and most recording systems limit the accurate estimation of the true desensitization rate (Zhou et al., 1998; Lovinger et al., 2002; Bouzat et al., 2008), which may partially account for the great variability of desensitization rates found in the literature. Outside-out patches rapidly perfused with ACh, which allows for a more accurate determination of the desensitization rate, show current decay time constants of ∼0.4 milliseconds (Bouzat et al., 2008). Owing to their fast decay, α7 peak responses occur in advance of complete solution exchange. Therefore, more accurate EC50 values are obtained if the net charge, which represents the time integration of all channel activation, rather than the peak current, is used for the analysis of the concentration-effect relationship (Papke and Porter Papke, 2002) (Fig. 6A).

Fig. 6.
Fig. 6.

α7 single-channel and macroscopic currents. (A) Typical whole-cell currents elicited by different ACh concentrations (from 10 to 1000 μM) from cells transfected with human α7. At left, a schematic representation of a macroscopic current with the measured parameters. Both the maximal current (peak) and the net charge (net) can be used to construct dose-response curves as shown in the figure. (B) Single-channel activity from cell-attached patches of cells expressing human α7 appears as very brief (∼0.1–0.3 milliseconds) and isolated openings or less often as short bursts. Channel openings are shown as upward deflections. Membrane potential, –70 mV; filter, 9 kHz. At right, a typical open duration histogram (Bouzat et al., 2008).

At the single-channel level, channel activity appears as isolated brief pulses (0.1–0.3 milliseconds) flanked by long closed periods and, less often, as two or three brief pulses in quick succession (bursts) (Fig. 6B). Thus, α7 has a very low open probability. Single-channel openings exhibit a broad distribution of current amplitudes, probably owing to limited time resolution of the brief openings, with a maximum of ∼10 pA at –70 mV (Mike et al., 2000; Bouzat et al., 2008; Andersen et al., 2013; daCosta and Sine, 2013; Yan et al., 2015).

Although there is no general consensus for an α7 kinetic model, an interesting aspect is that the temporal pattern of single ACh-activated currents is similar at 10 μM or 1 mM ACh (Bouzat et al., 2008) (Fig. 6B). This lack of concentration-dependence combined with the fact that most receptor activation episodes consist of a single opening with a duration similar to the desensitization time constant suggests that desensitization is the predominant pathway for channel closing, a unique feature among nAChRs. Control of open-channel lifetime through desensitization has potential consequences for inter-response latency at a synapse where the neurotransmitter pulse is transient. Recovery from desensitization depends on agonist concentration and exposure duration, since different desensitized states may exist. Desensitized α7 receptors expressed in human embryonic kidney cells recover with a time constant of ∼1 second (Bouzat et al., 2008), whereas 15–30 seconds are required for full recovery in the hippocampus (Frazier et al., 1998). Thus, after α7 brief response, a latency of several seconds is required to generate another response of full amplitude. The fast desensitization and brief open duration may avoid cell toxicity caused by increased intracellular Ca2+ owing to α7 overstimulation.

Another intriguing aspect of α7 activation is the relationship between ACh occupancy and activation. We set out to determine how many of the five identical agonist binding sites are required to activate α7 by developing a strategy that utilizes coexpression of an inactivated binding-site subunit and a reporter amplitude subunit. This allows for the determination of the number of ACh-occupied sites from the amplitude of each individual single-channel opening (Rayes et al., 2009; Andersen et al., 2011, 2013). The results revealed that ACh occupancy of only one of five α7 binding sites is necessary for activation, and that open-channel lifetime of a single-occupied receptor is indistinguishable from that of receptors containing five intact binding sites (Andersen et al., 2013). Also, occupancy of a single site by the antagonist methylcaconitine (Palma et al., 1996) or α-BTX (daCosta et al., 2015) will inhibit α7 function.

Whole-cell experiments have revealed the physiologic consequence of having more sites than those required for activation; saturation of receptors in cells expressing a wild-type and a binding-site mutant subunit (α7Y188T) is achieved at higher ACh concentrations when the proportion of receptors with fewer functional binding sites increases (Andersen et al., 2013; Williams et al., 2011a). This suggests that α7 is a highly sensitive sensor of ACh and is therefore adapted to function with submaximal occupancy of its sites, a property appropriate for volume transmission.

The unique activation properties of α7 also suggest that any slight change in the energy barriers between active, closed, and/or desensitized states may have a deep impact on receptor function, which makes these receptors very sensitive drug targets.

α7 Modulation as a Therapeutic Strategy

In addition to agonists and antagonists that bind to the orthosteric site, a large number of compounds modulate α7 function by binding to allosteric sites. These compounds may act as: 1) positive allosteric modulators (PAMs) that potentiate currents only in the presence of the agonist; 2) allosteric agonists that activate receptors from nonorthosteric sites; 3) negative allosteric modulators (NAMs), which either act as open-channel blockers by binding to the pore or inhibit activation allosterically; and 4) silent allosteric modulators (SAMs) that have no effect on orthosteric agonist responses but block allosteric modulation (Fig. 7).

Fig. 7.
Fig. 7.

Allosteric modulatory sites in α7. Structural model of the α7 receptor viewed from the side representing several potential sites for allosteric modulators. At the TMD, the intrasubunit transmembrane cavity is a site for a great variety of compounds that may elicit different pharmacological effects (potentiation (PAMs), inhibition (NAMs), no effect (SAMs), or activation (allosteric agonists)). PNU-120596 docked into this cavity is shown. Open-channel blockers inhibit response by transiently blocking the flux of ions through the pore. At the ECD, different potential sites for inhibitors and potentiators have been proposed (Ludwig et al., 2010; Spurny et al., 2015).

Since stimulation of α7 improves attention, cognitive performance, and neuronal resistance to injury in addition to eliciting robust analgesic and anti-inflammatory effects, α7 potentiation has emerged as a potential therapeutic strategy, and the search for novel potentiators is an active research field. The potential therapeutic use of several α7 partial agonists and PAMs on animals and humans has been documented in several recent reviews (e.g., Wallace and Porter, 2011; Thomsen and Mikkelsen, 2012; Lendvai et al., 2013; Dineley et al., 2015) (Table 1). Still, no drug has reached phase III clinical stage.

View this table:
TABLE 1

α7 modulators with potential clinical applications.

Compared with agonists, PAMs are promising therapeutic tools because they: 1) better maintain the temporal spatial characteristics of endogenous activation; 2) show higher selectivity, since the orthosteric site is more conserved among nAChRs than allosteric sites (Yang et al., 2012); 3) allow greater diversity in structure and final effects; 4) reduce tolerance attributable to α7 desensitization; and 5) act as neuronal protectors (Kalappa et al., 2013; Sun et al., 2013; Uteshev, 2014). In particular, because neuronal damage elevates choline levels near the site of injury, the presence of a PAM may not require coapplication of an agonist for the mediation of a local neuroprotective effect (Uteshev, 2014). Therefore, it is increasingly accepted that targeting allosteric sites can provide novel medications with greater structural diversity and specificity.

PAMs have been classified on the basis of their macroscopic effects as type I or type II (Fig. 8). Type I PAMs mainly enhance agonist-induced peak currents without significantly affecting current decay and do not reactivate desensitized receptors, whereas type II PAMs delay desensitization and reactivate desensitized receptors (Bertrand and Gopalakrishnan, 2007; Arias and Bouzat, 2010; Williams et al., 2011b). The ratio of the changes in net charge/peak current induced by type I PAMs is close to one, whereas it is higher than one in the presence of type II PAMs (Andersen et al., 2016; Williams et al., 2011c).

Fig. 8.
Fig. 8.

Macroscopic and single-channel current profiles of human α7 in the presence of typical type I and type II PAMs. Macroscopic current profiles have been used to classify PAMs into type II (i.e., PNU-120596 and PAM-2), which increase the decay time constant, or type I, which only increase the peak current (5-HI and NS-1738). Left: Macroscopic currents elicited by ACh in the absence (black) and presence of the specified PAM (gray traces). Right: Traces of 50–100 μM ACh-activated single α7 channels in the absence or in the presence of 1 μM PNU-120596, 5 μM PAM-2, 2 mM 5-HI, 10 μM NS-1738. Membrane potential: ­–70 mV. Channel openings are shown as upward deflections. All PAMs enhance open channel lifetime and elicit activation episodes formed by successive opening events.

Single-channel recordings provide an invaluable tool for understanding the foundations of these macroscopic effects. In the presence of either type I or type II PAMs, ACh-activated α7 channels show prolonged open durations and appear in longer activation episodes, revealing that both PAM types affect activation kinetics (Andersen et al., 2016) (Fig. 8). The most efficacious PAM to date is PNU-120596, a type II PAM (Hurst et al., 2005). This compound elicits significantly prolonged openings that appear grouped in bursts, which in turn coalesce into long activation periods of several seconds, referred to as clusters (daCosta et al., 2011, 2015; Williams et al., 2011b; Pałczyńska et al., 2012; Andersen et al., 2016). However, the single-channel profile in the presence of a weaker type II PAM, PAM-2 (3-furan-2-yl-N-p-tolyl-acrylamide) (Arias et al., 2011), more closely resembles that of type I 5-HI or NS-1738 PAMs than that of type II PNU-120596 (Fig. 8). Thus, when analyzed at the molecular level, potentiation is more complex than initially believed. Moreover, PAMs showing macroscopic intermediate type I/II properties were proposed (Dunlop et al., 2009; Malysz et al., 2009; Dinklo et al., 2011; Sahdeo et al., 2014; Chatzidaki and Millar, 2015). Therefore, the classification of type I and type II appears to be an oversimplification resulting mainly from macroscopic observations, and a more thorough classification may be required.

It is a generally accepted statement that type II PAMs may increase the energetic barrier for desensitization, which allows successive opening/closing events (daCosta et al., 2011) and/or reversal of some forms of agonist-induced desensitization (Williams et al., 2011b). Also, it has been proposed that PNU-120596 binds predominantly to a fast desensitized state and induces a set of conformations in which the opening of the pore is energetically more favorable (Szabo et al., 2014). On the other hand, only the decrease in the energetic barrier for opening has been proposed as the underlying mechanism for enhancement of peak currents by type I PAMs (Williams et al., 2011b; Hurst et al., 2013). Such a decrease might explain the appearance of bursts of openings owing to rapid reopening of the closed channel. However, it would only explain the increase in open-channel duration if reopening were so fast that the associated brief closings could not be detected, thus making openings appear longer. Alternatively, the increase in open duration could be the result of either slight changes in desensitization that are not detectable from whole-cell macroscopic currents or to the induction of different open states. Thus, there seems to be more than one mechanism by which PAMs prolong open-channel lifetime and activation episodes.

α7 PAM potentiation is particularly dependent on temperature. For PNU-120596, such dependence is revealed by decreased potentiated macroscopic currents (Dunlop et al., 2009; Williams et al., 2012) and the absence of long clusters (Andersen et al., 2016) at physiologic temperature compared with room temperature. Thus, for better extrapolation to the in vivo situation, in vitro studies should be carried out at physiologic temperatures.

α7 Allosteric Binding Sites

Computational studies (Dey and Chen, 2011), electrophysiological studies from mutant or chimeric receptors (Bertrand et al., 2008; Young et al., 2008; Collins et al., 2011; daCosta and Sine, 2013), crystallographic studies, (Spurny et al., 2015), and NMR studies (Bondarenko et al., 2014) have suggested the existence of several allosteric binding sites, some of which are common to other pLGICs (Sauguet et al., 2014).

The Intrasubunit Transmembrane Cavity.

In silico and electrophysiological studies show that several PAMs, including LY-2087101, PNU-120596, and TQS bind to an intrasubunit transmembrane cavity (Young et al., 2008) (Fig. 7). An α7 receptor with mutations at five residues lining this cavity was not potentiated by PNU-120596, PAM-2, or type I PAM NS-1738, indicating common structural determinants for their potentiation (daCosta et al., 2011; Andersen et al., 2016). The macrocyclic lactone ivermectin (a type I PAM) also appears to bind in close proximity to this intrasubunit site (Collins and Millar, 2010), although it binds at an intersubunit transmembrane site in the glutamate-activated Cys-loop receptor (Hibbs and Gouaux, 2011).

This cavity is also the site for allosteric agonists that mediate α7 activation in the absence of an orthosteric agonist (Gill et al., 2011, 2012, 2013; Pałczyńska et al., 2012). Single-channel activity of α7 in the presence of allosteric agonists resembles that of the receptor in the presence of ACh and a PAM. Both are characterized by long bursts instead of isolated brief ACh-elicited openings, indicating activation with significantly reduced desensitization (Pałczyńska et al., 2012).

Moreover, α7-selective allosteric modulators showing subtle structural changes and displaying distinct pharmacological effects (typical of type I PAMs, type II PAMs, NAMs, SAMs, and allosteric agonists) may bind to this common site (Gill et al., 2013; Gill-Thind et al., 2015). Thus, the intrasubunit transmembrane cavity appears to be a promiscuous binding site with a strategic location for allosteric modulation. Furthermore, this cavity may be a common modulatory site within the pLGIC superfamily from which a large variety of different compounds that bind to and mediate a great spectrum of allosteric effects (Corradi et al., 2011; Nury et al., 2011; Jayakar et al., 2013; Sauguet et al., 2014).

Extracellular Allosteric Binding Sites.

The putative binding site of galantamine, an α7 potentiator, is located at the outer surface of the ECD in the vicinity of the ACh site (Hansen and Taylor, 2007; Ludwig et al., 2010). Three different allosteric sites in the ECD of the α7/AChBP chimera were also identified by X-ray crystallography (Spurny et al., 2015; Fig. 7). Although all the allosteric binders behaved on human α7 as negative allosteric modulators, it was proposed that their chemical modification could lead to a change in functional activity.

Binding to potential ECD sites has been proposed for the type I PAMs 5-HI and NS-1738, although other reports support a TMD location (Placzek et al., 2004; Bertrand et al., 2008; Hu and Lovinger, 2008; Gronlien et al., 2010; Collins et al., 2011; Andersen et al., 2016). A virtual screening revealed that some PAMs that bind to the TMD, such as PNU-120596 and TQS, also dock into potential allosteric sites at the ECD (Dey and Chen, 2011). Therefore, for any given PAM, multiple binding sites or domains may be involved in the conformational changes associated with potentiation, which could account for these controversial results. Also, until the location of an allosteric binding site is unequivocally defined, it is advisable to refer to structural determinants of potentiation instead of a binding site.

Despite the large body of experimental evidence supporting α7 potentiation as a promising therapeutic strategy, there are still many unsolved challenges: 1) Potentiation by exogenous agonists may inhibit α7 response owing to desensitization. Thus, PAMs might have therapeutic benefits in situations where stronger agonist responses are desirable. 2) Given the presence of other nAChRs and homologous receptors, high PAM selectivity is required. However, PAMs targeting multiple receptors might show better efficacy (Iturriaga-Vásquez et al., 2015; Möller-Acuña et al., 2015). 3) Excessive receptor activation, particularly with efficacious nondesensitizing PAMs, might lead to cytotoxicity, which is an issue of concern and controversy (Ng et al., 2007; Liu et al., 2009; Williams et al., 2012; Guerra-Álvarez et al., 2015; Uteshev, 2016). 4) The ubiquitous distribution of α7 and its interplay with different signal pathways could make the cell response to a given PAM variable among cell types or conditions. Given the broad spectrum of effects and molecular mechanisms of PAMs, it is probable that each patient or pathologic situation could require a unique PAM.

Concluding Remarks

α7 has emerged as an important drug target for improving cognition and memory in several neuropsychiatric disorders, and as a target for inflammatory processes. α7 is unique owing to its high calcium permeability and fast desensitization, and it behaves as a ACh-sensitive sensor harboring a built-in filtering mechanism against excessive stimulation. Transient calcium responses are further sustained by the release of calcium from intracellular sources, and several signaling pathways are also activated because α7 has a dual ionotropic/metabotropic nature. Its ubiquitous location and pleiotropic effects make α7 an interesting but complex drug target. A better understanding of the molecular basis underlying allosteric modulation and its wide spectrum of effects, as well as the availability of high resolution structures of α7, will help in the rational design of therapeutics for the receptor.

Acknowledgments

ASPET thanks Dr. Katie Strong for copyediting of this article.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Bouzat, Corradi.

Footnotes

    • Received March 7, 2016.
    • Accepted May 5, 2016.

  • This work was supported by grants from Universidad Nacional del Sur (UNS), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), FONCYT, and the Bill and Melinda Gates Foundation to C.B.

  • dx.doi.org/10.1124/mol.116.104240.

Abbreviations

ACh
acetylcholine
α-BTX
α-bungarotoxin
ECD
extracellular domain
JAK
Janus kinase
LY-2087101
(2-amino-5-keto)thiazole), [2-[(4-fluorophenyl)amino]-4-methyl-5-thiazolyl]-3-thienyl-methanone
nAChR
nicotinic acetylcholine receptor
NAM
negative allosteric modulators
NS-1738
1-(5-chloro-2-hydroxyphenyl)-3-(2-chloro-5-trifluoromethylphenyl)urea
PAM
positive allosteric modulator
pLGIC
pentameric ligand-gated ion channels
PNU-120596
1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea
SAM
silent allosteric modulator
STAT
signal transducer and activator of transcription
TMD
transmembrane domain
TQS
4-(naphthalen-1-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide

References

  1. ↵
    1. Albuquerque EX,
    2. Alkondon M,
    3. Pereira EF,
    4. Castro NG,
    5. Schrattenholz A,
    6. Barbosa CT,
    7. Bonfante-Cabarcas R,
    8. Aracava Y,
    9. Eisenberg HM, and
    10. Maelicke A
    (1997) Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 280:1117–1136.
    OpenUrlFREE Full Text
  2. ↵
    1. Albuquerque EX,
    2. Pereira EFR,
    3. Alkondon M, and
    4. Rogers SW
    (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89:73–120.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Althoff T,
    2. Hibbs RE,
    3. Banerjee S, and
    4. Gouaux E
    (2014) X-ray structures of GluCl in apo states reveal a gating mechanism of Cys-loop receptors. Nature 512:333–337.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Andersen N,
    2. Corradi J,
    3. Bartos M,
    4. Sine SM, and
    5. Bouzat C
    (2011) Functional relationships between agonist binding sites and coupling regions of homomeric Cys-loop receptors. J Neurosci 31:3662–3669.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Andersen N,
    2. Corradi J,
    3. Sine SM, and
    4. Bouzat C
    (2013) Stoichiometry for activation of neuronal α7 nicotinic receptors. Proc Natl Acad Sci USA 110:20819–20824.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Andersen ND,
    2. Nielsen BE,
    3. Corradi J,
    4. Tolosa MF,
    5. Feuerbach D,
    6. Arias HR, and
    7. Bouzat C
    (2016) Exploring the positive allosteric modulation of human α7 nicotinic receptors from a single-channel perspective. Neuropharmacology 107:189–200.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Arias HR and
    2. Bouzat C
    (2010) Activation and modulation of the nicotinic receptor. J Pediatr Biochem 1:53–73.
    OpenUrl
  8. ↵
    1. Arias HR,
    2. Gu R-X,
    3. Feuerbach D,
    4. Guo B-B,
    5. Ye Y, and
    6. Wei D-Q
    (2011) Novel positive allosteric modulators of the human α7 nicotinic acetylcholine receptor. Biochemistry 50:5263–5278.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Báez-Pagán CA,
    2. Delgado-Vélez M, and
    3. Lasalde-Dominicci JA
    (2015) Activation of the macrophage α7 nicotinic acetylcholine receptor and control of inflammation. J Neuroimmune Pharmacol 10:468–476.
    OpenUrlCrossRefPubMed
    1. Bagdas D,
    2. Targowska-Duda KM,
    3. López JJ,
    4. Perez EG,
    5. Arias HR, and
    6. Damaj MI
    (2015) The Antinociceptive and Antiinflammatory Properties of 3-furan-2-yl-N-p-tolyl-acrylamide, a Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptors in Mice. Anesth Analg 121:1369–1377.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Bartos M,
    2. Corradi J, and
    3. Bouzat C
    (2009) Structural basis of activation of cys-loop receptors: the extracellular-transmembrane interface as a coupling region. Mol Neurobiol 40:236–252.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Bertrand D,
    2. Bertrand S,
    3. Cassar S,
    4. Gubbins E,
    5. Li J, and
    6. Gopalakrishnan M
    (2008) Positive allosteric modulation of the α7 nicotinic acetylcholine receptor: ligand interactions with distinct binding sites and evidence for a prominent role of the M2-M3 segment. Mol Pharmacol 74:1407–1416.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Bertrand D and
    2. Gopalakrishnan M
    (2007) Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol 74:1155–1163.
    OpenUrlCrossRefPubMed
    1. Bitner RS,
    2. Bunnelle WH,
    3. Decker MW,
    4. Drescher KU,
    5. Kohlhaas KL,
    6. Markosyan S,
    7. Marsh KC,
    8. Nikkel AL,
    9. Browman K,
    10. Radek R,
    11. et al.
    (2010) In vivo pharmacological characterization of a novel selective α7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer’s disease. J Pharmacol Exp Ther 334:875–886.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Bocquet N,
    2. Nury H,
    3. Baaden M,
    4. Le Poupon C,
    5. Changeux J-P,
    6. Delarue M, and
    7. Corringer P-J
    (2009) X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation. Nature 457:111–114.
    OpenUrlCrossRefPubMed
    1. Boess FG,
    2. De Vry J,
    3. Erb C,
    4. Flessner T,
    5. Hendrix M,
    6. Luithle J,
    7. Methfessel C,
    8. Riedl B,
    9. Schnizler K,
    10. Van Der Staay F,
    11. et al.
    (2007) The Novel α7 Nicotinic Acetylcholine Receptor Agonist benzofuran-2-carboxamide Improves Working and Recognition Memory in Rodents. Pharmacology 321:716–725.
    OpenUrl
  17. ↵
    1. Bondarenko V,
    2. Mowrey DD,
    3. Tillman TS,
    4. Seyoum E,
    5. Xu Y, and
    6. Tang P
    (2014) NMR structures of the human α7 nAChR transmembrane domain and associated anesthetic binding sites. Biochim Biophys Acta 1838:1389–1395.
    OpenUrl
  18. ↵
    1. Bonfante-Cabarcas R,
    2. Swanson KL,
    3. Alkondon M, and
    4. Albuquerque EX
    (1996) Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. IV. Regulation by external Ca++ of alpha-bungarotoxin-sensitive receptor function and of rectification induced by internal Mg++. J Pharmacol Exp Ther 277:432–444.
    OpenUrlAbstract/FREE Full Text
    1. Bouzat C
    (2012) New insights into the structural bases of activation of Cys-loop receptors. J Physiol Paris 106:23–33.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Bouzat C,
    2. Bartos M,
    3. Corradi J, and
    4. Sine SM
    (2008) The interface between extracellular and transmembrane domains of homomeric Cys-loop receptors governs open-channel lifetime and rate of desensitization. J Neurosci 28:7808–7819.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Bouzat C,
    2. Gumilar F,
    3. Spitzmaul G,
    4. Wang H-L,
    5. Rayes D,
    6. Hansen SB,
    7. Taylor P, and
    8. Sine SM
    (2004) Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel. Nature 430:896–900.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Brejc K,
    2. van Dijk WJ,
    3. Klaassen RV,
    4. Schuurmans M,
    5. van Der Oost J,
    6. Smit AB, and
    7. Sixma TK
    (2001) Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 411:269–276.
    OpenUrlCrossRefPubMed
    1. Callahan PM,
    2. Hutchings EJ,
    3. Kille NJ,
    4. Chapman JM, and
    5. Terry AV Jr.
    (2013) Positive allosteric modulator of α7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates. Neuropharmacology 67:201–212.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Castillo M,
    2. Mulet J,
    3. Bernal JA,
    4. Criado M,
    5. Sala F, and
    6. Sala S
    (2006) Improved gating of a chimeric alpha7-5HT3A receptor upon mutations at the M2-M3 extracellular loop. FEBS Lett 580:256–260.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Castillo M,
    2. Mulet J,
    3. Gutiérrez LM,
    4. Ortiz JA,
    5. Castelán F,
    6. Gerber S,
    7. Sala S,
    8. Sala F, and
    9. Criado M
    (2005) Dual role of the RIC-3 protein in trafficking of serotonin and nicotinic acetylcholine receptors. J Biol Chem 280:27062–27068.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Cecchini M and
    2. Changeux J-P
    (2015) The nicotinic acetylcholine receptor and its prokaryotic homologues: Structure, conformational transitions & allosteric modulation. Neuropharmacology 96 (Pt B):137–149.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Changeux JP,
    2. Kasai M, and
    3. Lee CY
    (1970) Use of a snake venom toxin to characterize the cholinergic receptor protein. Proc Natl Acad Sci USA 67:1241–1247.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Chatzidaki A and
    2. Millar NS
    (2015) Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol 97:408–417.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Collins T and
    2. Millar NS
    (2010). Nicotinic acetylcholine receptor transmembrane mutations convert ivermectin from a positive to a negative allosteric modulator. Mol Pharmacol 78:198–204.
  30. ↵
    1. Collins T,
    2. Young GT, and
    3. Millar NS
    (2011) Competitive binding at a nicotinic receptor transmembrane site of two α7-selective positive allosteric modulators with differing effects on agonist-evoked desensitization. Neuropharmacology 61:1306–1313.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Corradi J,
    2. Andersen N, and
    3. Bouzat C
    (2011) A novel mechanism of modulation of 5-HT₃A receptors by hydrocortisone. Biophys J 100:42–51.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Corradi J,
    2. Gumilar F, and
    3. Bouzat C
    (2009) Single-channel kinetic analysis for activation and desensitization of homomeric 5-HT(3)A receptors. Biophys J 97:1335–1345.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Corringer P-J,
    2. Poitevin F,
    3. Prevost MS,
    4. Sauguet L,
    5. Delarue M, and
    6. Changeux J-P
    (2012) Structure and pharmacology of pentameric receptor channels: from bacteria to brain. Structure 20:941–956.
    OpenUrlCrossRefPubMed
  34. ↵
    1. daCosta CJB,
    2. Free CR,
    3. Corradi J,
    4. Bouzat C, and
    5. Sine SM
    (2011) Single-channel and structural foundations of neuronal α7 acetylcholine receptor potentiation. J Neurosci 31:13870–13879.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. daCosta CJB,
    2. Free CR, and
    3. Sine SM
    (2015) Stoichiometry for α-bungarotoxin block of α7 acetylcholine receptors. Nat Commun 6:8057.
    OpenUrlCrossRefPubMed
  36. ↵
    1. daCosta CJB and
    2. Sine SM
    (2013) Stoichiometry for drug potentiation of a pentameric ion channel. Proc Natl Acad Sci USA 110:6595–6600.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Dajas-Bailador FA,
    2. Mogg AJ, and
    3. Wonnacott S
    (2002) Intracellular Ca2+ signals evoked by stimulation of nicotinic acetylcholine receptors in SH-SY5Y cells: contribution of voltage-operated Ca2+ channels and Ca2+ stores. J Neurochem 81:606–614.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Dani JA and
    2. Bertrand D
    (2007) Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47:699–729.
    OpenUrlCrossRefPubMed
  39. ↵
    1. de Jonge WJ and
    2. Ulloa L
    (2007) The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 151:915–929.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Dellisanti CD,
    2. Yao Y,
    3. Stroud JC,
    4. Wang Z-Z, and
    5. Chen L
    (2007) Crystal structure of the extracellular domain of nAChR alpha1 bound to alpha-bungarotoxin at 1.94 A resolution. Nat Neurosci 10:953–962.
    OpenUrlCrossRefPubMed
  41. ↵
    1. De Rosa MJ,
    2. Esandi MdelC,
    3. Garelli A,
    4. Rayes D, and
    5. Bouzat C
    (2005) Relationship between alpha 7 nAChR and apoptosis in human lymphocytes. J Neuroimmunol 160:154–161.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Deutsch SI,
    2. Burket JA,
    3. Benson AD, and
    4. Urbano MR
    (2016) The 15q13.3 deletion syndrome: Deficient α(7)-containing nicotinic acetylcholine receptor-mediated neurotransmission in the pathogenesis of neurodevelopmental disorders. Prog Neuropsychopharmacol Biol Psychiatry 64:109–117.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Dey R and
    2. Chen L
    (2011) In search of allosteric modulators of a7-nAChR by solvent density guided virtual screening. J Biomol Struct Dyn 28:695–715.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Dickinson JA,
    2. Kew JNC, and
    3. Wonnacott S
    (2008) Presynaptic alpha 7- and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol Pharmacol 74:348–359.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Dineley KT,
    2. Pandya AA, and
    3. Yakel JL
    (2015) Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci 36:96–108.
    OpenUrlCrossRef
  46. ↵
    1. Dinklo T,
    2. Shaban H,
    3. Thuring JW,
    4. Lavreysen H,
    5. Stevens KE,
    6. Zheng L,
    7. Mackie C,
    8. Grantham C,
    9. Vandenberk I,
    10. Meulders G,
    11. et al.
    (2011) Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazolemethanol (JNJ-1930942), a novel positive allosteric modulator of the α7 nicotinic acetylcholine receptor. J Pharmacol Exp Ther 336:560–574.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Dunlop J,
    2. Lock T,
    3. Jow B,
    4. Sitzia F,
    5. Grauer S,
    6. Jow F,
    7. Kramer A,
    8. Bowlby MR,
    9. Randall A,
    10. Kowal D,
    11. et al.
    (2009) Old and new pharmacology: positive allosteric modulation of the α7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b′]di pyrrole-1(2H)-carboxamide). J Pharmacol Exp Ther 328:766–776.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Egea J,
    2. Buendia I,
    3. Parada E,
    4. Navarro E,
    5. León R, and
    6. Lopez MG
    (2015) Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection. Biochem Pharmacol 97:463–472.
    OpenUrlCrossRefPubMed
    1. Feuerbach D,
    2. Lingenhoehl K,
    3. Olpe HR,
    4. Vassout A,
    5. Gentsch C,
    6. Chaperon F,
    7. Nozulak J,
    8. Enz A,
    9. Bilbe G,
    10. McAllister K,
    11. et al.
    (2009) The selective nicotinic acetylcholine receptor α7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology 56:254–263.
    OpenUrlPubMed
    1. Feuerbach D,
    2. Nozulak J,
    3. Lingenhoehl K,
    4. McAllister K, and
    5. Hoyer D
    (2007) JN403, in vitro characterization of a novel nicotinic acetylcholine receptor α7 selective agonist. Neurosci Lett 416:61–65.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Frazier CJ,
    2. Rollins YD,
    3. Breese CR,
    4. Leonard S,
    5. Freedman R, and
    6. Dunwiddie TV
    (1998) Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci 18:1187–1195.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Gill JK,
    2. Dhankher P,
    3. Sheppard TD,
    4. Sher E, and
    5. Millar NS
    (2012) A series of α7 nicotinic acetylcholine receptor allosteric modulators with close chemical similarity but diverse pharmacological properties. Mol Pharmacol 81:710–718.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Gill JK,
    2. Chatzidaki A,
    3. Ursu D,
    4. Sher E, and
    5. Millar NS
    (2013) Contrasting properties of α7-selective orthosteric and allosteric agonists examined on native nicotinic acetylcholine receptors. PLoS One 8:e55047 10.1371/journal.pone.0055047.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Gill JK,
    2. Savolainen M,
    3. Young GT,
    4. Zwart R,
    5. Sher E, and
    6. Millar NS
    (2011) Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci USA 108:5867–5872.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Gill-Thind JK,
    2. Dhankher P,
    3. D’Oyley JM,
    4. Sheppard TD, and
    5. Millar NS
    (2015) Structurally similar allosteric modulators of α7 nicotinic acetylcholine receptors exhibit five distinct pharmacological effects. J Biol Chem 290:3552–3562.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Gotti C and
    2. Clementi F
    (2004) Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74:363–396.
    OpenUrlCrossRefPubMed
    1. Grønlien JH,
    2. Ween H,
    3. Thorin-Hagene K,
    4. Cassar S,
    5. Li J,
    6. Briggs CA,
    7. Gopalakrishnan M, and
    8. Malysz J
    (2010) Importance of M2-M3 loop in governing properties of genistein at the α7 nicotinic acetylcholine receptor inferred from α7/5-HT3A chimera. Eur J Pharmacol 647:37–47.
    OpenUrlCrossRefPubMed
  58. ↵
    1. Gu S,
    2. Matta JA,
    3. Lord B,
    4. Harrington AW,
    5. Sutton SW,
    6. Davini WB, and
    7. Bredt DS
    (2016) Brain α7 Nicotinic Acetylcholine Receptor Assembly Requires NACHO. Neuron 89:948–955.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Guan Y-Z,
    2. Jin X-D,
    3. Guan L-X,
    4. Yan H-C,
    5. Wang P,
    6. Gong Z,
    7. Li S-J,
    8. Cao X,
    9. Xing Y-L, and
    10. Gao T-M
    (2015) Nicotine inhibits microglial proliferation and is neuroprotective in global ischemia rats. Mol Neurobiol 51:1480–1488.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Guan ZZ,
    2. Zhang X,
    3. Ravid R, and
    4. Nordberg A
    (2000) Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer’s disease. J Neurochem 74:237–243.
    OpenUrlCrossRefPubMed
  61. ↵
    1. Guerra-Álvarez M,
    2. Moreno-Ortega AJ,
    3. Navarro E,
    4. Fernández-Morales JC,
    5. Egea J,
    6. López MG, and
    7. Cano-Abad MF
    (2015) Positive allosteric modulation of alpha-7 nicotinic receptors promotes cell death by inducing Ca(2+) release from the endoplasmic reticulum. J Neurochem 133:309–319.
    OpenUrlCrossRefPubMed
    1. Hajós M,
    2. Hurst RS,
    3. Hoffmann WE,
    4. Krause M,
    5. Wall TM,
    6. Higdon NR, and
    7. Groppi VE
    (2005) The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 312:1213–1222.
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Hansen SB and
    2. Taylor P
    (2007) Galanthamine and non-competitive inhibitor binding to ACh-binding protein: evidence for a binding site on non-alpha-subunit interfaces of heteromeric neuronal nicotinic receptors. J Mol Biol 369:895–901.
    OpenUrlCrossRefPubMed
    1. Hashimoto K
    (2015) Tropisetron and its targets in Alzheimer’s disease. Expert Opin Ther Targets 19:1–5.
    OpenUrlCrossRefPubMed
    1. Hashimoto T,
    2. Ichiki T,
    3. Watanabe A,
    4. Hurt-Camejo E,
    5. Michaëlsson E,
    6. Ikeda J,
    7. Inoue E,
    8. Matsuura H,
    9. Tokunou T,
    10. Kitamoto S,
    11. et al.
    (2014) Stimulation of α7 nicotinic acetylcholine receptor by AR-R17779 suppresses atherosclerosis and aortic aneurysm formation in apolipoprotein E-deficient mice. Vascul Pharmacol 61:49–55.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Hassaine G,
    2. Deluz C,
    3. Grasso L,
    4. Wyss R,
    5. Tol MB,
    6. Hovius R,
    7. Graff A,
    8. Stahlberg H,
    9. Tomizaki T,
    10. Desmyter A,
    11. et al.
    (2014) X-ray structure of the mouse serotonin 5-HT3 receptor. Nature 512:276–281.
    OpenUrlCrossRefPubMed
    1. Hauser TA,
    2. Kucinski A,
    3. Jordan KG,
    4. Gatto GJ,
    5. Wersinger SR,
    6. Hesse RA,
    7. Stachowiak EK,
    8. Stachowiak MK,
    9. Papke RL,
    10. Lippiello PM,
    11. et al.
    (2009) TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 78:803–812.
    OpenUrlCrossRefPubMed
  68. ↵
    1. Hibbs RE and
    2. Gouaux E
    (2011) Principles of activation and permeation in an anion-selective Cys-loop receptor. Nature 474:54–60.
    OpenUrlCrossRefPubMed
  69. ↵
    1. Hilf RJC and
    2. Dutzler R
    (2008) X-ray structure of a prokaryotic pentameric ligand-gated ion channel. Nature 452:375–379.
    OpenUrlCrossRefPubMed
  70. ↵
    1. Hilf RJC and
    2. Dutzler R
    (2009) Structure of a potentially open state of a proton-activated pentameric ligand-gated ion channel. Nature 457:115–118.
    OpenUrlCrossRefPubMed
  71. ↵
    1. Hu X-Q and
    2. Lovinger DM
    (2008) The L293 residue in transmembrane domain 2 of the 5-HT3A receptor is a molecular determinant of allosteric modulation by 5-hydroxyindole. Neuropharmacology 54:1153–1165.
    OpenUrlCrossRefPubMed
  72. ↵
    1. Hurst R,
    2. Rollema H, and
    3. Bertrand D
    (2013) Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther 137:22–54.
    OpenUrlCrossRefPubMed
  73. ↵
    1. Hurst RS,
    2. Hajós M,
    3. Raggenbass M,
    4. Wall TM,
    5. Higdon NR,
    6. Lawson JA,
    7. Rutherford-Root KL,
    8. Berkenpas MB,
    9. Hoffmann WE,
    10. Piotrowski DW,
    11. et al.
    (2005) A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 25:4396–4405.
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Iturriaga-Vásquez P,
    2. Alzate-Morales J,
    3. Bermudez I,
    4. Varas R, and
    5. Reyes-Parada M
    (2015) Multiple binding sites in the nicotinic acetylcholine receptors: An opportunity for polypharmacolgy. Pharmacol Res 101:9–17.
    OpenUrlCrossRefPubMed
  75. ↵
    1. Jayakar SS,
    2. Dailey WP,
    3. Eckenhoff RG, and
    4. Cohen JB
    (2013) Identification of propofol binding sites in a nicotinic acetylcholine receptor with a photoreactive propofol analog. J Biol Chem 288:6178–6189.
    OpenUrlAbstract/FREE Full Text
  76. ↵
    1. Jones AK,
    2. Buckingham SD, and
    3. Sattelle DB
    (2010) Proteins interacting with nicotinic acetylcholine receptors: expanding functional and therapeutic horizons. Trends Pharmacol Sci 31:455–462.
    OpenUrlCrossRefPubMed
  77. ↵
    1. Jones IW and
    2. Wonnacott S
    (2004) Precise localization of alpha7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. J Neurosci 24:11244–11252.
    OpenUrlAbstract/FREE Full Text
  78. ↵
    1. Kabbani N,
    2. Nordman JC,
    3. Corgiat BA,
    4. Veltri DP,
    5. Shehu A,
    6. Seymour VA, and
    7. Adams DJ
    (2013) Are nicotinic acetylcholine receptors coupled to G proteins? BioEssays 35:1025–1034.
    OpenUrlCrossRefPubMed
  79. ↵
    1. Kadir A,
    2. Almkvist O,
    3. Wall A,
    4. Långström B, and
    5. Nordberg A
    (2006) PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease. Psychopharmacology (Berl) 188:509–520.
    OpenUrlCrossRefPubMed
  80. ↵
    1. Kalappa BI,
    2. Sun F,
    3. Johnson SR,
    4. Jin K, and
    5. Uteshev VV
    (2013) A positive allosteric modulator of α7 nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischaemia. Br J Pharmacol 169:1862–1878.
    OpenUrlCrossRefPubMed
    1. Karamihalev S,
    2. Prickaerts J, and
    3. van Goethem NP
    (2014) Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia. Behav Brain Res 272:248–251.
    OpenUrlCrossRefPubMed
  82. ↵
    1. Kawashima K and
    2. Fujii T
    (2004) Expression of non-neuronal acetylcholine in lymphocytes and its contribution to the regulation of immune function. Front Biosci 9:2063–2085.
    OpenUrlCrossRefPubMed
  83. ↵
    1. King JR,
    2. Nordman JC,
    3. Bridges SP,
    4. Lin M-K, and
    5. Kabbani N
    (2015) Identification and characterization of a G protein-binding cluster in α7 nicotinic acetylcholine receptors. J Biol Chem 290:20060–20070.
    OpenUrlAbstract/FREE Full Text
  84. ↵
    1. Langley JN
    (1905) On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. J Physiol 33:374–413.
    OpenUrlCrossRefPubMed
  85. ↵
    1. Lape R,
    2. Colquhoun D, and
    3. Sivilotti LG
    (2008) On the nature of partial agonism in the nicotinic receptor superfamily. Nature 454:722–727.
    OpenUrlCrossRefPubMed
  86. ↵
    1. Le Novère N and
    2. Changeux JP
    (2001) LGICdb: the ligand-gated ion channel database. Nucleic Acids Res 29:294–295.
    OpenUrlAbstract/FREE Full Text
  87. ↵
    1. Le Novère N and
    2. Changeux JP
    (1995) Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J Mol Evol 40:155–172.
    OpenUrlCrossRefPubMed
  88. ↵
    1. Lee WY and
    2. Sine SM
    (2005) Principal pathway coupling agonist binding to channel gating in nicotinic receptors. Nature 438:243–247.
    OpenUrlCrossRefPubMed
  89. ↵
    1. Lendvai B,
    2. Kassai F,
    3. Szájli A, and
    4. Némethy Z
    (2013) α7 nicotinic acetylcholine receptors and their role in cognition. Brain Res Bull 93:86–96.
    OpenUrlCrossRefPubMed
  90. ↵
    1. Lester HA,
    2. Dibas MI,
    3. Dahan DS,
    4. Leite JF, and
    5. Dougherty DA
    (2004) Cys-loop receptors: new twists and turns. Trends Neurosci 27:329–336.
    OpenUrlCrossRefPubMed
    1. Levin ED,
    2. Bettegowda C,
    3. Blosser J, and
    4. Gordon J
    (1999) AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol 10:675–680.
    OpenUrlCrossRefPubMed
  92. ↵
    1. Li S-X,
    2. Huang S,
    3. Bren N,
    4. Noridomi K,
    5. Dellisanti CD,
    6. Sine SM, and
    7. Chen L
    (2011) Ligand-binding domain of an α7-nicotinic receptor chimera and its complex with agonist. Nat Neurosci 14:1253–1259.
    OpenUrlCrossRefPubMed
  93. ↵
    1. Liu Q,
    2. Huang Y,
    3. Shen J,
    4. Steffensen S, and
    5. Wu J
    (2012) Functional α7β2 nicotinic acetylcholine receptors expressed in hippocampal interneurons exhibit high sensitivity to pathological level of amyloid β peptides. BMC Neurosci 13:155.
    OpenUrlCrossRefPubMed
  94. ↵
    1. Liu Q,
    2. Huang Y,
    3. Xue F,
    4. Simard A,
    5. DeChon J,
    6. Li G,
    7. Zhang J,
    8. Lucero L,
    9. Wang M,
    10. Sierks M,
    11. et al.
    (2009) A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 29:918–929.
    OpenUrlAbstract/FREE Full Text
  95. ↵
    Lovinger DM, Sikes S, and Zhou Q (2002) Rapid drug superfusion and kinetic analysis, in Methods in Alcohol-Related Neuroscience Research (Liu Y et al. eds) pp 159–187, CRC Press, Boca Raton, FL.
  96. ↵
    1. Ludwig J,
    2. Höffle-Maas A,
    3. Samochocki M,
    4. Luttmann E,
    5. Albuquerque EX,
    6. Fels G, and
    7. Maelicke A
    (2010) Localization by site-directed mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain. J Recept Signal Transduct Res 30:469–483.
    OpenUrlCrossRefPubMed
    1. Mackin KD,
    2. Maus AD,
    3. Pereira EF,
    4. Albuquerque EX, and
    5. Conti-Fine BM
    (1998) Human vascular endothelial cells express functional nicotinic acetylcholine receptors. J Pharmacol Exp Ther 287:435–439.
    OpenUrlAbstract/FREE Full Text
  98. ↵
    1. Malysz J,
    2. Grønlien JH,
    3. Anderson DJ,
    4. Håkerud M,
    5. Thorin-Hagene K,
    6. Ween H,
    7. Wetterstrand C,
    8. Briggs CA,
    9. Faghih R,
    10. Bunnelle WH,
    11. et al.
    (2009) In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile. J Pharmacol Exp Ther 330:257–267.
    OpenUrlAbstract/FREE Full Text
  99. ↵
    1. Martelli D,
    2. McKinley MJ, and
    3. McAllen RM
    (2014) The cholinergic anti-inflammatory pathway: a critical review. Auton Neurosci 182:65–69.
    OpenUrlCrossRefPubMed
  100. ↵
    1. Maus AD,
    2. Pereira EF,
    3. Karachunski PI,
    4. Horton RM,
    5. Navaneetham D,
    6. Macklin K,
    7. Cortes WS,
    8. Albuquerque EX, and
    9. Conti-Fine BM
    (1998) Human and rodent bronchial epithelial cells express functional nicotinic acetylcholine receptors. Mol Pharmacol 54:779–788.
    OpenUrlAbstract/FREE Full Text
    1. Menze ET,
    2. Esmat A,
    3. Tadros MG,
    4. Abdel-Naim AB, and
    5. Khalifa AE
    (2015) Genistein improves 3-NPA-induced memory impairment in ovariectomized rats: impact of its antioxidant, anti-inflammatory and acetylcholinesterase modulatory properties. PLoS One 10:e0117223.
    OpenUrlCrossRefPubMed
    1. Menze ET,
    2. Esmat A,
    3. Tadros MG,
    4. Khalifa AE, and
    5. Abdel-Naim AB
    (2016) Genistein improves sensorimotor gating: Mechanisms related to its neuroprotective effects on the striatum. Neuropharmacology 105:35–46.
    OpenUrlCrossRefPubMed
  103. ↵
    1. Mike A,
    2. Castro NG, and
    3. Albuquerque EX
    (2000) Choline and acetylcholine have similar kinetic properties of activation and desensitization on the alpha7 nicotinic receptors in rat hippocampal neurons. Brain Res 882:155–168.
    OpenUrlCrossRefPubMed
  104. ↵
    1. Miledi R and
    2. Potter LT
    (1971) Acetylcholine receptors in muscle fibres. Nature 233:599–603.
    OpenUrlCrossRefPubMed
  105. ↵
    1. Millar NS
    (2008) RIC-3: a nicotinic acetylcholine receptor chaperone. Br J Pharmacol 153 (Suppl 1):S177–S183.
    OpenUrlCrossRefPubMed
  106. ↵
    1. Miller PS and
    2. Aricescu AR
    (2014) Crystal structure of a human GABAA receptor. Nature 512:270–275.
    OpenUrlCrossRefPubMed
  107. ↵
    1. Möller-Acuña P,
    2. Contreras-Riquelme JS,
    3. Rojas-Fuentes C,
    4. Nuñez-Vivanco G,
    5. Alzate-Morales J,
    6. Iturriaga-Vásquez P,
    7. Arias HR, and
    8. Reyes-Parada M
    (2015) Similarities between the binding sites of SB-206553 at serotonin type 2 and alpha7 acetylcholine nicotinic receptors: rationale for its polypharmacological profile. PLoS One 10:e0134444.
    OpenUrlCrossRefPubMed
  108. ↵
    1. Monod J,
    2. Wyman J, and
    3. Changeux JP
    (1965) On the nature of allosteric transitions: A plausible model. J Mol Biol 12:88–118.
    OpenUrlCrossRefPubMed
  109. ↵
    1. Moretti M,
    2. Zoli M,
    3. George AA,
    4. Lukas RJ,
    5. Pistillo F,
    6. Maskos U,
    7. Whiteaker P, and
    8. Gotti C
    (2014) The novel α7β2-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterization. Mol Pharmacol 86:306–317.
    OpenUrlAbstract/FREE Full Text
  110. ↵
    1. Mowrey DD,
    2. Liu Q,
    3. Bondarenko V,
    4. Chen Q,
    5. Seyoum E,
    6. Xu Y,
    7. Wu J, and
    8. Tang P
    (2013) Insights into distinct modulation of α7 and α7β2 nicotinic acetylcholine receptors by the volatile anesthetic isoflurane. J Biol Chem 288:35793–35800.
    OpenUrlAbstract/FREE Full Text
  111. ↵
    1. Mukhtasimova N,
    2. Lee WY,
    3. Wang H-L, and
    4. Sine SM
    (2009) Detection and trapping of intermediate states priming nicotinic receptor channel opening. Nature 459:451–454.
    OpenUrlCrossRefPubMed
  112. ↵
    1. Nemecz A and
    2. Taylor P
    (2011) Creating an α7 nicotinic acetylcholine recognition domain from the acetylcholine-binding protein: crystallographic and ligand selectivity analyses. J Biol Chem 286:42555–42565.
    OpenUrlAbstract/FREE Full Text
  113. ↵
    1. Neri M,
    2. Bonassi S, and
    3. Russo P
    (2012) Genetic variations in CHRNA7 or CHRFAM7 and susceptibility to dementia. Curr Drug Targets 13:636–643.
    OpenUrlCrossRefPubMed
  114. ↵
    1. Ng HJ,
    2. Whittemore ER,
    3. Tran MB,
    4. Hogenkamp DJ,
    5. Broide RS,
    6. Johnstone TB,
    7. Zheng L,
    8. Stevens KE, and
    9. Gee KW
    (2007) Nootropic α7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Natl Acad Sci USA 104:8059–8064.
    OpenUrlAbstract/FREE Full Text
  115. ↵
    1. Ni M,
    2. Yang Z-W,
    3. Li D-J,
    4. Li Q,
    5. Zhang S-H,
    6. Su D-F,
    7. Xie H-H, and
    8. Shen F-M
    (2010) A potential role of alpha-7 nicotinic acetylcholine receptor in cardiac angiogenesis in a pressure-overload rat model. J Pharmacol Sci 114:311–319.
    OpenUrlCrossRef
    1. Nikiforuk A,
    2. Kos T,
    3. Potasiewicz A, and
    4. Popik P
    (2015) Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats. Eur Neuropsychopharmacol 25:1300–1313.
    OpenUrlCrossRefPubMed
  117. ↵
    1. Nordman JC and
    2. Kabbani N
    (2012) An interaction between α7 nicotinic receptors and a G-protein pathway complex regulates neurite growth in neural cells. J Cell Sci 125:5502–5513.
    OpenUrlAbstract/FREE Full Text
  118. ↵
    1. Nury H,
    2. Van Renterghem C,
    3. Weng Y,
    4. Tran A,
    5. Baaden M,
    6. Dufresne V,
    7. Changeux J-P,
    8. Sonner JM,
    9. Delarue M, and
    10. Corringer P-J
    (2011) X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel. Nature 469:428–431.
    OpenUrlCrossRefPubMed
    1. O’Donnell CJ,
    2. Rogers BN,
    3. Bronk BS,
    4. Bryce DK,
    5. Coe JW,
    6. Cook KK,
    7. Duplantier AJ,
    8. Evrard E,
    9. Hajós M,
    10. Hoffmann WE,
    11. et al.
    (2010) Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel α 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition models. J Med Chem 53:1222–1237.
    OpenUrlCrossRefPubMed
    1. Olincy A,
    2. Harris JG,
    3. Johnson LL,
    4. Pender V,
    5. Kongs S,
    6. Allensworth D,
    7. Ellis J,
    8. Zerbe GO,
    9. Leonard S,
    10. Stevens KE,
    11. et al.
    (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630–638.
    OpenUrlCrossRefPubMed
  121. ↵
    1. Pałczyńska MM,
    2. Jindrichova M,
    3. Gibb AJ, and
    4. Millar NS
    (2012) Activation of α7 nicotinic receptors by orthosteric and allosteric agonists: influence on single-channel kinetics and conductance. Mol Pharmacol 82:910–917.
    OpenUrlAbstract/FREE Full Text
  122. ↵
    1. Palma E,
    2. Bertrand S,
    3. Binzoni T, and
    4. Bertrand D
    (1996) Neuronal nicotinic alpha 7 receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine. J Physiol 491:151–161.
    OpenUrlCrossRefPubMed
  123. ↵
    1. Papke RL and
    2. Porter Papke JK
    (2002) Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis. Br J Pharmacol 137:49–61.
    OpenUrlCrossRefPubMed
  124. ↵
    1. Parada E,
    2. Egea J,
    3. Buendia I,
    4. Negredo P,
    5. Cunha AC,
    6. Cardoso S,
    7. Soares MP, and
    8. López MG
    (2013) The microglial α7-acetylcholine nicotinic receptor is a key element in promoting neuroprotection by inducing heme oxygenase-1 via nuclear factor erythroid-2-related factor 2. Antioxid Redox Signal 19:1135–1148.
    OpenUrlCrossRefPubMed
  125. ↵
    1. Park HJ,
    2. Lee PH,
    3. Ahn YW,
    4. Choi YJ,
    5. Lee G,
    6. Lee D-Y,
    7. Chung ES, and
    8. Jin BK
    (2007) Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur J Neurosci 26:79–89.
    OpenUrlCrossRefPubMed
  126. ↵
    1. Patrick J,
    2. Ballivet M,
    3. Boas L,
    4. Claudio T,
    5. Forrest J,
    6. Ingraham H,
    7. Mason P,
    8. Stengelin S,
    9. Ueno S, and
    10. Heinemann S
    (1983) Molecular cloning of the acetylcholine receptor. Cold Spring Harb Symp Quant Biol 48:71–78.
    OpenUrlAbstract/FREE Full Text
  127. ↵
    1. Paulo JA,
    2. Brucker WJ, and
    3. Hawrot E
    (2009) Proteomic analysis of an alpha7 nicotinic acetylcholine receptor interactome. J Proteome Res 8:1849–1858.
    OpenUrlCrossRefPubMed
    1. Pichat P,
    2. Bergis OE,
    3. Terranova J-P,
    4. Urani A,
    5. Duarte C,
    6. Santucci V,
    7. Gueudet C,
    8. Voltz C,
    9. Steinberg R,
    10. Stemmelin J,
    11. et al.
    (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32:17–34.
    OpenUrlCrossRefPubMed
  129. ↵
    1. Placzek AN,
    2. Grassi F,
    3. Papke T,
    4. Meyer EM, and
    5. Papke RL
    (2004) A single point mutation confers properties of the muscle-type nicotinic acetylcholine receptor to homomeric alpha7 receptors. Mol Pharmacol 66:169–177.
    OpenUrlAbstract/FREE Full Text
    1. Prickaerts J,
    2. van Goethem NP,
    3. Chesworth R,
    4. Shapiro G,
    5. Boess FG,
    6. Methfessel C,
    7. Reneerkens OAH,
    8. Flood DG,
    9. Hilt D,
    10. Gawryl M,
    11. et al.
    (2012) EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology 62:1099–1110.
    OpenUrlCrossRefPubMed
    1. Quik M,
    2. Zhang D,
    3. McGregor M, and
    4. Bordia T
    (2015) Alpha7 nicotinic receptors as therapeutic targets for Parkinson’s disease. Biochem Pharmacol 97:399–407.
    OpenUrlCrossRefPubMed
  132. ↵
    1. Rayes D,
    2. De Rosa MJ,
    3. Sine SM, and
    4. Bouzat C
    (2009) Number and locations of agonist binding sites required to activate homomeric Cys-loop receptors. J Neurosci 29:6022–6032.
    OpenUrlAbstract/FREE Full Text
  133. ↵
    1. Razani-Boroujerdi S,
    2. Boyd RT,
    3. Dávila-García MI,
    4. Nandi JS,
    5. Mishra NC,
    6. Singh SP,
    7. Pena-Philippides JC,
    8. Langley R, and
    9. Sopori ML
    (2007) T cells express alpha7-nicotinic acetylcholine receptor subunits that require a functional TCR and leukocyte-specific protein tyrosine kinase for nicotine-induced Ca2+ response. J Immunol 179:2889–2898.
    OpenUrlAbstract/FREE Full Text
  134. ↵
    1. Sahdeo S,
    2. Wallace T,
    3. Hirakawa R,
    4. Knoflach F,
    5. Bertrand D,
    6. Maag H,
    7. Misner D,
    8. Tombaugh GC,
    9. Santarelli L,
    10. Brameld K,
    11. et al.
    (2014) Characterization of RO5126946, a Novel α7 nicotinic acetylcholine receptor-positive allosteric modulator. J Pharmacol Exp Ther 350:455–468.
    OpenUrlAbstract/FREE Full Text
  135. ↵
    1. Sauguet L,
    2. Shahsavar A,
    3. Poitevin F,
    4. Huon C,
    5. Menny A,
    6. Nemecz À,
    7. Haouz A,
    8. Changeux J-P,
    9. Corringer P-J, and
    10. Delarue M
    (2014) Crystal structures of a pentameric ligand-gated ion channel provide a mechanism for activation. Proc Natl Acad Sci USA 111:966–971.
    OpenUrlAbstract/FREE Full Text
  136. ↵
    1. Schaaf CP
    (2014) Nicotinic acetylcholine receptors in human genetic disease. Genet Med 16:649–656.
    OpenUrlCrossRefPubMed
  137. ↵
    1. Schirmer SU,
    2. Eckhardt I,
    3. Lau H,
    4. Klein J,
    5. DeGraaf YC,
    6. Lips KS,
    7. Pineau C,
    8. Gibbins IL,
    9. Kummer W,
    10. Meinhardt A,
    11. et al.
    (2011) The cholinergic system in rat testis is of non-neuronal origin. Reproduction 142:157–166.
    OpenUrlAbstract/FREE Full Text
  138. ↵
    1. Séguéla P,
    2. Wadiche J,
    3. Dineley-Miller K,
    4. Dani JA, and
    5. Patrick JW
    (1993) Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci 13:596–604.
    OpenUrlAbstract
  139. ↵
    1. Sharma G and
    2. Vijayaraghavan S
    (2001) Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proc Natl Acad Sci USA 98:4148–4153.
    OpenUrlAbstract/FREE Full Text
  140. ↵
    1. Shen JX and
    2. Yakel JL
    (2012) Functional α7 nicotinic ACh receptors on astrocytes in rat hippocampal CA1 slices. J Mol Neurosci 48:14–21.
    OpenUrlCrossRefPubMed
    1. Shiina A,
    2. Shirayama Y,
    3. Niitsu T,
    4. Hashimoto T,
    5. Yoshida T,
    6. Hasegawa T,
    7. Haraguchi T,
    8. Kanahara N,
    9. Shiraishi T,
    10. Fujisaki M,
    11. et al.
    (2010) A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry 9:27.
    OpenUrlCrossRefPubMed
  142. ↵
    1. Shytle RD,
    2. Mori T,
    3. Townsend K,
    4. Vendrame M,
    5. Sun N,
    6. Zeng J,
    7. Ehrhart J,
    8. Silver AA,
    9. Sanberg PR, and
    10. Tan J
    (2004) Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 89:337–343.
    OpenUrlCrossRefPubMed
  143. ↵
    1. Sine SM
    (2012) End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease. Physiol Rev 92:1189–1234.
    OpenUrlAbstract/FREE Full Text
  144. ↵
    1. Sine SM and
    2. Engel AG
    (2006) Recent advances in Cys-loop receptor structure and function. Nature 440:448–455.
    OpenUrlCrossRefPubMed
  145. ↵
    1. Sinkus ML,
    2. Graw S,
    3. Freedman R,
    4. Ross RG,
    5. Lester HA, and
    6. Leonard S
    (2015) The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function. Neuropharmacology 96 (Pt B):274–288.
    OpenUrlCrossRefPubMed
  146. ↵
    1. Sinkus ML,
    2. Lee MJ,
    3. Gault J,
    4. Logel J,
    5. Short M,
    6. Freedman R,
    7. Christian SL,
    8. Lyon J, and
    9. Leonard S
    (2009) A 2-base pair deletion polymorphism in the partial duplication of the alpha7 nicotinic acetylcholine gene (CHRFAM7A) on chromosome 15q14 is associated with schizophrenia. Brain Res 1291:1–11.
    OpenUrlCrossRefPubMed
  147. ↵
    1. Spurny R,
    2. Debaveye S,
    3. Farinha A,
    4. Veys K,
    5. Vos AM,
    6. Gossas T,
    7. Atack J,
    8. Bertrand S,
    9. Bertrand D,
    10. Danielson UH,
    11. et al.
    (2015) Molecular blueprint of allosteric binding sites in a homologue of the agonist-binding domain of the α7 nicotinic acetylcholine receptor. Proc Natl Acad Sci USA 112:E2543–E2552.
    OpenUrlAbstract/FREE Full Text
  148. ↵
    1. Stuckenholz V,
    2. Bacher M,
    3. Balzer-Geldsetzer M,
    4. Alvarez-Fischer D,
    5. Oertel WH,
    6. Dodel RC, and
    7. Noelker C
    (2013) The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice. J Parkinsons Dis 3:161–172.
    OpenUrlCrossRefPubMed
  149. ↵
    1. Sun F,
    2. Jin K, and
    3. Uteshev VV
    (2013) A type-II positive allosteric modulator of α7 nAChRs reduces brain injury and improves neurological function after focal cerebral ischemia in rats. PLoS One 8:e73581 10.1371/journal.pone.0073581.
    OpenUrlCrossRefPubMed
    1. Sydserff S,
    2. Sutton EJ,
    3. Song D,
    4. Quirk MC,
    5. Maciag C,
    6. Li C,
    7. Jonak G,
    8. Gurley D,
    9. Gordon JC,
    10. Christian EP,
    11. et al.
    (2009) Selective α7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol 78:880–888.
    OpenUrlCrossRefPubMed
  151. ↵
    1. Szabo AK,
    2. Pesti K,
    3. Mike A, and
    4. Vizi ES
    (2014) Mode of action of the positive modulator PNU-120596 on α7 nicotinic acetylcholine receptors. Neuropharmacology 81:42–54.
    OpenUrlCrossRefPubMed
  152. ↵
    1. Taly A and
    2. Changeux J-P
    (2008) Functional organization and conformational dynamics of the nicotinic receptor: a plausible structural interpretation of myasthenic mutations. Ann N Y Acad Sci 1132:42–52.
    OpenUrlCrossRefPubMed
    1. Targowska-Duda KM,
    2. Wnorowski A,
    3. Budzynska B,
    4. Jozwiak K,
    5. Biala G, and
    6. Arias HR
    (2016) The positive allosteric modulator of α7 nicotinic acetylcholine receptors, 3-furan-2-yl-N-p-tolyl-acrylamide, enhances memory processes and stimulates ERK1/2 phosphorylation in mice. Behav Brain Res 302:142–151.
    OpenUrlCrossRefPubMed
  154. ↵
    1. Tasneem A,
    2. Iyer LM,
    3. Jakobsson E, and
    4. Aravind L
    (2005) Identification of the prokaryotic ligand-gated ion channels and their implications for the mechanisms and origins of animal Cys-loop ion channels. Genome Biol 6:R4.
    OpenUrlCrossRefPubMed
    1. Terry AV Jr.,
    2. Callahan PM, and
    3. Hernandez CM
    (2015) Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders. Biochem Pharmacol 97:388–398.
    OpenUrlCrossRefPubMed
  156. ↵
    1. Thomsen MS and
    2. Mikkelsen JD
    (2012) Type I and II positive allosteric modulators differentially modulate agonist-induced up-regulation of α7 nicotinic acetylcholine receptors. J Neurochem 123:73–83.
    OpenUrlCrossRefPubMed
  157. ↵
    1. Thomsen MS,
    2. Zwart R,
    3. Ursu D,
    4. Jensen MM,
    5. Pinborg LH,
    6. Gilmour G,
    7. Wu J,
    8. Sher E, and
    9. Mikkelsen JD
    (2015) α7 and β2 nicotinic acetylcholine receptor subunits form heteromeric receptor complexes that are expressed in the human cortex and display distinct pharmacological properties. PLoS One 10:e0130572 10.1371/journal.pone.0130572.
    OpenUrlCrossRefPubMed
    1. Timmermann DB,
    2. Grønlien JH,
    3. Kohlhaas KL,
    4. Nielsen EØ,
    5. Dam E,
    6. Jørgensen TD,
    7. Ahring PK,
    8. Peters D,
    9. Holst D,
    10. Christensen JK,
    11. et al.
    (2007) An allosteric modulator of the α7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 323:294–307.
    OpenUrlAbstract/FREE Full Text
  159. ↵
    1. Tsuneki H,
    2. Klink R,
    3. Léna C,
    4. Korn H, and
    5. Changeux JP
    (2000) Calcium mobilization elicited by two types of nicotinic acetylcholine receptors in mouse substantia nigra pars compacta. Eur J Neurosci 12:2475–2485.
    OpenUrlCrossRefPubMed
  160. ↵
    1. Uteshev VV
    (2014) The therapeutic promise of positive allosteric modulation of nicotinic receptors. Eur J Pharmacol 727:181–185.
    OpenUrlCrossRefPubMed
  161. ↵
    1. Uteshev V
    (2016) Are positive allosteric modulators of α7 nAChRs clinically safe? J Neurochem 136:217–219.
    OpenUrlCrossRefPubMed
    1. Van Kampen M,
    2. Selbach K,
    3. Schneider R,
    4. Schiegel E,
    5. Boess F, and
    6. Schreiber R
    (2004) AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology (Berl) 172:375–383.
    OpenUrlCrossRefPubMed
    1. van Westerloo DJ,
    2. Giebelen IA,
    3. Florquin S,
    4. Bruno MJ,
    5. Larosa GJ,
    6. Ulloa L,
    7. Tracey KJ, and
    8. van der Poll T
    (2006) The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice. Gastroenterology 130:1822–1830.
    OpenUrlCrossRefPubMed
    1. Vukelic M,
    2. Qing X,
    3. Redecha P,
    4. Koo G, and
    5. Salmon JE
    (2013) Cholinergic receptors modulate immune complex-induced inflammation in vitro and in vivo. J Immunol 191:1800–1807.
    OpenUrlAbstract/FREE Full Text
  165. ↵
    1. Wallace TL and
    2. Bertrand D
    (2013) Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia. Expert Opin Ther Targets 17:139–155.
    OpenUrlCrossRefPubMed
    1. Wallace TL,
    2. Callahan PM,
    3. Tehim A,
    4. Bertrand D,
    5. Tombaugh G,
    6. Wang S,
    7. Xie W,
    8. Rowe WB,
    9. Ong V,
    10. Graham E,
    11. et al.
    (2011) RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther 336:242–253.
    OpenUrlAbstract/FREE Full Text
  167. ↵
    1. Wallace TL and
    2. Porter RHP
    (2011) Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol 82:891–903.
    OpenUrlCrossRefPubMed
  168. ↵
    1. Wang Y,
    2. Xiao C,
    3. Indersmitten T,
    4. Freedman R,
    5. Leonard S, and
    6. Lester HA
    (2014) The duplicated α7 subunits assemble and form functional nicotinic receptors with the full-length α7. J Biol Chem 289:26451–26463.
    OpenUrlAbstract/FREE Full Text
  169. ↵
    1. Wessler I and
    2. Kirkpatrick CJ
    (2008) Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol 154:1558–1571.
    OpenUrlCrossRefPubMed
  170. ↵
    1. Williams DK,
    2. Peng C,
    3. Kimbrell MR, and
    4. Papke RL
    (2012) Intrinsically low open probability of α7 nicotinic acetylcholine receptors can be overcome by positive allosteric modulation and serum factors leading to the generation of excitotoxic currents at physiological temperatures. Mol Pharmacol 82:746–759.
    OpenUrlAbstract/FREE Full Text
  171. ↵
    1. Williams DK,
    2. Stokes C,
    3. Horenstein NA, and
    4. Papke RL
    (2011a) The effective opening of nicotinic acetylcholine receptors with single agonist binding sites. J Gen Physiol 137:369–384.
    OpenUrlAbstract/FREE Full Text
  172. ↵
    1. Williams DK,
    2. Wang J, and
    3. Papke RL
    (2011b) Investigation of the molecular mechanism of the α7 nicotinic acetylcholine receptor positive allosteric modulator PNU-120596 provides evidence for two distinct desensitized states. Mol Pharmacol 80:1013–1032.
    OpenUrlAbstract/FREE Full Text
  173. ↵
    1. Williams DK,
    2. Wang J, and
    3. Papke RL
    (2011c) Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Biochem Pharmacol 82:915–930.
    OpenUrlCrossRefPubMed
  174. ↵
    1. Williams ME,
    2. Burton B,
    3. Urrutia A,
    4. Shcherbatko A,
    5. Chavez-Noriega LE,
    6. Cohen CJ, and
    7. Aiyar J
    (2005) Ric-3 promotes functional expression of the nicotinic acetylcholine receptor alpha7 subunit in mammalian cells. J Biol Chem 280:1257–1263.
    OpenUrlAbstract/FREE Full Text
  175. ↵
    Wonnacott S and Barik J (2007) Nicotinic ACh Receptors. Tocris Rev 28, http://www.komabiotech.co.kr/pdf/nicotinic_ach_receptors_review.pdf.
  176. ↵
    1. Yan H,
    2. Pan N,
    3. Xue F,
    4. Zheng Y,
    5. Li C,
    6. Chang Y,
    7. Xu Z,
    8. Yang H, and
    9. Zhang J
    (2015) The coupling interface and pore domain codetermine the single-channel activity of the α7 nicotinic receptor. Neuropharmacology 95:448–458.
    OpenUrlCrossRefPubMed
  177. ↵
    1. Yang J-S,
    2. Seo SW,
    3. Jang S,
    4. Jung GY, and
    5. Kim S
    (2012) Rational engineering of enzyme allosteric regulation through sequence evolution analysis. PLOS Comput Biol 8:e1002612 10.1371/journal.pcbi.1002612.
    OpenUrlCrossRefPubMed
  178. ↵
    1. Young GT,
    2. Zwart R,
    3. Walker AS,
    4. Sher E, and
    5. Millar NS
    (2008) Potentiation of α7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci USA 105:14686–14691.
    OpenUrlAbstract/FREE Full Text
  179. ↵
    1. Zdanowski R,
    2. Krzyżowska M,
    3. Ujazdowska D,
    4. Lewicka A, and
    5. Lewicki S
    (2015) Role of α7 nicotinic receptor in the immune system and intracellular signaling pathways. Cent Eur J Immunol 40:373–379.
    OpenUrlPubMed
  180. ↵
    1. Zhang J,
    2. Xue F,
    3. Liu Y,
    4. Yang H, and
    5. Wang X
    (2013) The structural mechanism of the Cys-loop receptor desensitization. Mol Neurobiol 48:97–108.
    OpenUrlCrossRefPubMed
  181. ↵
    1. Zhou Q,
    2. Verdoorn TA, and
    3. Lovinger DM
    (1998) Alcohols potentiate the function of 5-HT3 receptor-channels on NCB-20 neuroblastoma cells by favouring and stabilizing the open channel state. J Physiol 507:335–352.
    OpenUrlCrossRefPubMed
  182. ↵
    1. Zia S,
    2. Ndoye A,
    3. Nguyen VT, and
    4. Grando SA
    (1997) Nicotine enhances expression of the alpha 3, alpha 4, alpha 5, and alpha 7 nicotinic receptors modulating calcium metabolism and regulating adhesion and motility of respiratory epithelial cells. Res Commun Mol Pathol Pharmacol 97:243–262.
    OpenUrlPubMed
  183. ↵
    1. Zimmermann I,
    2. Marabelli A,
    3. Bertozzi C,
    4. Sivilotti LG, and
    5. Dutzler R
    (2012) Inhibition of the prokaryotic pentameric ligand-gated ion channel ELIC by divalent cations. PLoS Biol 10:e1001429.
    OpenUrlCrossRefPubMed
  184. ↵
    1. Zoli M,
    2. Pistillo F, and
    3. Gotti C
    (2015) Diversity of native nicotinic receptor subtypes in mammalian brain. Neuropharmacology 96 (Pt B):302–311.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Rapid CommunicationMinireview—A Latin American Perspective on Ion Channels

α7 Modulation

Jeremías Corradi and Cecilia Bouzat
Molecular Pharmacology September 1, 2016, 90 (3) 288-299; DOI: https://doi.org/10.1124/mol.116.104240
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement